1,642 Shares in Laboratory Co. of America Holdings (NYSE:LH) Acquired by Curi RMB Capital LLC

Curi RMB Capital LLC acquired a new stake in shares of Laboratory Co. of America Holdings (NYSE:LH) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 1,642 shares of the medical research company’s stock, valued at approximately $367,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Diamond Hill Capital Management Inc. lifted its position in shares of Laboratory Co. of America by 1.5% in the third quarter. Diamond Hill Capital Management Inc. now owns 1,978,686 shares of the medical research company’s stock worth $442,197,000 after buying an additional 29,046 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Laboratory Co. of America by 16.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,865,460 shares of the medical research company’s stock worth $416,893,000 after acquiring an additional 263,105 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Laboratory Co. of America by 135.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,609,826 shares of the medical research company’s stock worth $327,616,000 after acquiring an additional 924,881 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Laboratory Co. of America by 2.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,417,645 shares of the medical research company’s stock valued at $288,519,000 after acquiring an additional 33,497 shares during the last quarter. Finally, Cooke & Bieler LP grew its holdings in shares of Laboratory Co. of America by 26.8% in the second quarter. Cooke & Bieler LP now owns 928,250 shares of the medical research company’s stock valued at $188,908,000 after purchasing an additional 196,119 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Piper Sandler upped their price target on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a research note on Monday, October 28th. Robert W. Baird increased their price target on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Barclays boosted their price objective on Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft upped their price objective on Laboratory Co. of America from $220.00 to $230.00 and gave the company a “hold” rating in a research report on Friday, August 2nd. Finally, Jefferies Financial Group lifted their target price on Laboratory Co. of America from $245.00 to $265.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Five investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $255.92.

Laboratory Co. of America Stock Down 1.2 %

NYSE:LH opened at $235.21 on Friday. The company has a market cap of $19.67 billion, a price-to-earnings ratio of 45.50, a price-to-earnings-growth ratio of 2.03 and a beta of 1.05. Laboratory Co. of America Holdings has a twelve month low of $191.97 and a twelve month high of $247.99. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.66. The stock has a fifty day simple moving average of $224.40 and a 200-day simple moving average of $215.63.

Laboratory Co. of America (NYSE:LH) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.48 by $0.02. The company had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $3.38 EPS. Analysts anticipate that Laboratory Co. of America Holdings will post 14.53 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.22%. Laboratory Co. of America’s payout ratio is currently 55.71%.

Insider Buying and Selling at Laboratory Co. of America

In related news, Director Kerrii B. Anderson sold 1,000 shares of the business’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the director now owns 13,722 shares of the company’s stock, valued at $3,156,060. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $227.05, for a total value of $454,100.00. Following the sale, the executive vice president now owns 3,670 shares of the company’s stock, valued at approximately $833,273.50. This represents a 35.27 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,189 shares of company stock valued at $2,190,936 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.